In re Brimonidine Patent Litigation: No infringement based on ANDA specifications and no invalidity based on an “obvious to try” analysis.

The article offers a case report presenting the arguments made at the U.S. District Court and Federal Circuit in In re Brimonidine Patent Litigation, and also discussing how each of these courts addressed the issues raised by the parties. In this case, the Federal Circuit reversed the U.S. District Court for the District of Delaware's holding that Exela PharmaSci, Inc. literally infringed U.S. Patent No. 6,641,834 and also reversed the District Court's decision.